Monitor for any future amendments that cross the 5% threshold or convert to a 13D filing, which would signal a shift in intent. For now, this is a routine administrative update with no trading implications.
Price Chart
Executive Summary
JPMorgan Chase & Co. filed an amended Schedule 13G disclosing beneficial ownership of 1,401,790 shares of LB Pharmaceuticals Inc. common stock, representing 4.3% of shares outstanding as of September 30, 2026. The filing is a routine passive stake update with no change in investment intent, and the stake remains below the 5% threshold, indicating no material escalation.
Key Financial Metrics
Key Facts
- JPMorgan Chase & Co. reported beneficial ownership of 1,401,790 shares of LB Pharmaceuticals Inc. common stock.
- The stake represents 4.3% of outstanding shares as of September 30, 2026.
- The filing is an amendment to Schedule 13G under Rule 13d-1(b), confirming passive investment intent.
- JPMorgan disclaims beneficial ownership of shares held by its subsidiaries, including JPMorgan Asset Management entities and JPMorgan Chase Bank.
Financial Impact
No financial impact — passive stake disclosure below 5% threshold.
Risk Factors
- No material risks identified from this filing.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0000019617-26-000360 |
| Document: 0000019617-26-000360-index.html | 0000019617-26-000360 |
| Document: 0000019617-26-000360.txt | 0000019617-26-000360 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 12d ago | SC 13G/A | $34.79 | awaiting T+60 | — | $39.75 (+14.26%) |
Oct 6, 2026 20d ago | EFFECT | $34.26 | awaiting T+60 | — | $39.75 (−16.02%) |
Sep 15, 2026 5w ago | 8-K | $43.04 | awaiting T+60 | — | $39.75 (−7.64%) |
Sep 3, 2026 7w ago | 8-K | $47.52 | awaiting T+60 | — | $39.75 (−16.35%) |
Aug 11, 2026 10w ago | 8-K | $45.33 | awaiting T+60 | — | $39.75 (−12.31%) |
Aug 11, 2026 10w ago | Press Release | $45.33 | awaiting T+60 | — | $39.75 (−12.31%) |
Jul 29, 2026 12w ago | 8-K | $39.00 $39.42 | ▲ +1.08% | ▼ −3.65% | $39.75 (+1.92%) |
Jul 22, 2026 13w ago | 8-K | $35.84 $36.69 | ▲ +2.37% | ▼ −0.89% | $39.75 (+10.91%) |
Jul 22, 2026 13w ago | Press Release | $35.84 $36.69 | ▲ +2.37% | ▼ −0.89% | $39.75 (+10.91%) |
Jun 10, 2026 19w ago | 8-K | $28.54 | awaiting T+60 | — | $39.75 (+39.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers